ARTICLE | Company News
Neurocrine, Sibia deal
April 15, 2013 7:00 AM UTC
NBIX received a non-exclusive license to use SIBI's transcription-based assay patents against a specific target. In exchange, SIBI receives access to NBIX's compound library to discover compounds dire...